Description: A Phase 1 Study of KSQ-4279 Alone and in Combination in Patients with Advanced Solid Tumors.
Mechanism of Action: USP1 inhibitor – USP1 is a de-ubiquitinating enzyme in the DDR pathway. USP1 inhibition leads to double stranded DNA breaks (synthetic lethality)
Target Patient Population: Solid Tumors
Study Design: Study drug is given orally daily. Currently in monotherapy in dose escalation. Phase 2 will follow with expansion in combinations with mFOLFOX, Gem/Carbo and Olaparib combinations.